Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation

• Status: Recruiting
• Trial end date: 2022-12-10
• Target enrollment: 0
• Participant gender: All

Summary

Post-inflammatory hyperpigmentation is a common pigmentary skin disorder that is refractory to treatment. The treatment for postinflammatory hyperpigmentation is limited. Recent studies have shown that the topical skin care product cysteamine cream has a significant decrease in melanin index without obvious side effects in other dark spots such as melasma. The goal of this study is to determine the safety and efficacy of topical cysteamine in the treatment of post-inflammatory hyperpigmentation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Collaborator: Scientis Pharma SA
• Treatments: Cysteamine

Criteria

Inclusion Criteria:

• Over 20 years old

• Patients with postinflammatory hyperpigmentation for more than 3 months.

Exclusion Criteria:

• Patients with topical hydroquinone, oral tranexamic acid and/or other skin whitening agents.

• Patients that receive or planning to receive laser treatment for spot removal during the study period.

• Individuals with allergic history to cysteamine or vehicle ingredients.

• Pregnant patients or patients planning to become pregnant during the time of the study.